1 Prime Therapeutics (Prime) recently released its latest clinical insights report, Metabolic dysfunction-associated steatohepatitis (MASH) A new era in liver health, which shares the latest clinical considerations regarding treatment of MASH, potential implications of the GLP-1 approval for MASH and what payers and providers should know about its impact on the marketplace
CJC-1295/Ipamorelin + MOTS-c: Our recommendation for serious athletes who want peak performance across both metabolic and hormonal pathways
The combined therapy with liraglutide and metformin (COMBI) seems to be more effective
Personalized Insights Encourages immune-supportive nutrition, mitochondrial-friendly habits, and recovery practices that promote balanced long-term wellness.
Long-term success will rely on marketing, easy onboarding, support tools and adherence encouragement, and delivering consistent, trusted consumer experiences
People are finding telehealth providers who will write that prescription and then dabbling in the market
